ClinicalTrials.gg
RecruitingNCT06191302Updated Mar 12, 2025

Post-acute COVID-19 Sequelae in Denmark

An observational study in Non-communicable Disease and COVID-19, sponsored by Hvidovre University Hospital. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-12.

Sponsored by Hvidovre University Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
800
Ages
18 Years and older
Sex
All
01

Study summary

Since the first SARS-CoV-2 cases in 2019, over 660 million COVID-19 cases have been reported globally, including 183 million in the EU. Up to 70% of those infected experience reduced organ function four months or more after a COVID-19 diagnosis, potentially increasing the risk of non-communicable diseases (NCDs). The post-acute phase (PAP) after COVID-19 (four months or more after the acute phase) can lead to impaired function in various organ systems, with a focus on the lungs, cardiovascular system, and kidneys. These three NCDs collectively impose a significant burden on individuals and society. Urgently, we need to understand the connection between COVID-19, PAP and NCDs, identifying robust biomarkers for early detection. This study examines PAP and associated risk factors, investigating the link between PAP and the heightened risk of lung, heart, and kidney complications. Utilizing data from a cohort of COVID-19 patients and a control group with respiratory diseases, the study aims to determine prevalence and risk ratios more precisely. The aim is to contribute to minimizing the risk of NCD development or exacerbation in current and future COVID-19 patients, enhancing our understanding of chronic disease development at the population leve

Read the detailed description

The post-acute phase (PAP) after COVID-19 (four months or more after the acute phase of COVID-19) can manifest with reduced function in multiple organ systems, with a particular focus on the lungs, cardiovascular system, and kidneys. Collectively, these three non-communicable diseases (NCDs) represent a significant burden for both the individual and society as a whole. There is an urgent need to elucidate this connection and build a more detailed understanding of the link between COVID-19\'s PAP and individual NCDs, as well as to identify robust biomarkers that can assist in the early identification of the development of these NCDs.

This study focuses on PAP and the associated risk factors in this later phase of the disease, examining the relationship between PAP and the increased risk of specifically lung, heart, and kidney complications in the Danish population. Additionally, data (medical records, registry data, patient reported outcomes and blood samples) from a cohort of former patients hospitalized with COVID-19, as well as a control group hospitalized with other respiratory diseases, are investigated to determine the prevalence and risk ratios in disease development more precisely.

The purpose of the study is to contribute to minimizing the risk of developing or worsening NCDs in current and future COVID-19 patients, as well as contributing to our understanding of chronic disease development at the population level. The study aims to investigate the hypothesis that biomarkers can predict if SARS-CoV-2 infection leads to increased and exacerbated non-communicable pulmonary, cardiovascular, and renal diseases.

Further, we address the unmet need to understand the molecular mechanisms responsible for the link between post-acute effects of SARS-CoV-2 and complications in the pulmonary, cardiovascular, and renal system. More specific we will investigate the molecular mechanisms responsible for the aetiology and decline in organ function.

The population in the registry study is the entire population of Denmark. The population in the clinical cohort consists of former patients who have been admitted to Hvidovre Hospital with the diagnosis OBS COVID. Participants consent to the use of residual material from their blood sample, taken during their hospitalization with the diagnosis OBS-COVID in the period 2020-2022 (index blood sample). After obtaining consent, patients come to Hvidovre Hospital, where a blood sample (follow-up blood sample) is taken, and an online questionnaire is completed and stored in REDCap. Blood samples are analyzed and compared with collected registry data and questionnaire data, after which the results are reported in international peer-reviewed journals.

02

Conditions studied

  • Non-communicable Disease
  • COVID-19

Keywords

  • Sequelae
  • Inflammation
  • Ageing
  • Non-communicable disease
03

In context

Noncommunicable Diseases

146 studies on the registry are indexed under Noncommunicable Diseases; 57 are open to participants now.

This study's planned enrollment of 800 is below the median of 1,674 across 48 observational studies indexed under Noncommunicable Diseases.

Browse Noncommunicable Diseases studies →

Lead sponsor

Hvidovre University Hospital is the lead sponsor of 299 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The participating patients are former patients admitted to Hvidovre Hospital with the diagnosis OBS-COVID

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a blood sample in the clinical biobank related to the OBS-COVID index admission
  • Aged above 18 years at time of index-admission

Exclusion criteria

Exclusion Criteria:

  • Patients without a Danish personal identification number
  • Patients who do not understand or speak Danish
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
800 participants (estimated)
Patient registry
No

Groups and cohorts

  • SARS-CoV-2 positive patients

    a cohort of former patients hospitalized with COVID-19

    Procedure: blood sample · Other: Online questionaire

  • SARS-CoV-2 negative patients

    a control group of former patients hospitalized with other respiratory diseases

    Procedure: blood sample · Other: Online questionaire

Interventions

  • Procedureblood sample

    Blood sample collected in the post-acute period (follow-up visit) will be analysed for biomarkers predictive for diseases related to and disease progression in various organ systems (e.g., cardiovascular, pulmonary, and renal systems), including e.g., Pro-BNP, NGAL, and interleukins.

  • OtherOnline questionaire

    The participants will complete an online questionnaire related to disease and health issues associated with COVID-19 and COVID-19 post-acute sequalae's and existing Non-Communicable Disease.

06

What researchers measure

Primary outcomes

  1. 1.Is there a difference in the incidence and disease progression of NCD (pulmonary, cardiovascular, and renal disease) in the PAP between SARS-CoV-2-positive patients and a control group of patients admitted with other respiratory diseases?

    Primary outcomes: * Incidence of incipient NCD * Change in health-state of pre-existing NCD

    Time frame: Follow-up from index-admission to March 1, 2026

  2. 2. Is there a difference in the association of admission biomarkers and incidence, severity, and disease progression of NCD in PAP, between SARS-CoV-2 positive patients and a control group of patients admitted with other respiratory diseases?

    • Level in admission biomarkers associated with incipient or worsening of NCD in PAP

    Time frame: Follow-up from index-admission to March 1, 2026

  3. 3. Which biomarkers are involved in development or disease progression of NCDs in PAP?

    Principal outcomes: * Identify in vivo biomarkers in admission and follow-up blood samples associated with tissue /organ damage, and inflammation * Investigate in vitro molecular mechanisms in follow-up blood samples by examining cellular morphology, metabolism, stress response, fibrosis, viability, proliferation, senescence, and inflammation.

    Time frame: Follow-up from index-admission to March 1, 2026

Other outcomes

  1. 1.Is there a difference in the incidence and disease progression of NCD (pulmonary, cardiovascular, and renal disease) in the PAP between SARS-CoV-2-positive patients and a control group of patients admitted with other respiratory diseases?

    Other outcomes: * Incidence of incipient NCD stratified by the socioeconomic position of patients * Change in health-state of pre-existing NCD stratified by the socioeconomic position of patients

    Time frame: Follow-up from index-admission to March 1, 2026

  2. 2. Is there a difference in the association of admission biomarkers and incidence, severity, and disease progression of NCD in PAP, between SARS-CoV-2 positive patients and a control group of patients admitted with other respiratory diseases?

    • Level in admission biomarkers associated with symptoms, lower quality of life, functional impairment in PAP.

    Time frame: Follow-up from index-admission to March 1, 2026

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Only aggregated data can be available for other researchers due to Danish Data Protection Law

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2024 (actual). Primary completion is estimated for Mar 2026, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2024
First posted
Jan 5, 2024
StartActual
Sep 10, 2024
Primary completionEst.
Mar 1, 2026
CompletionEst.
Mar 1, 2026
Last update
Mar 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06191302
Responsible party
Ove Andersen (Research Director, professor,, Hvidovre University Hospital) — Principal investigator
First posted
Jan 5, 2024
Start date
Sep 10, 2024
Primary completion
Mar 1, 2026 (estimated)
Completion
Mar 1, 2026 (estimated)
Last update
Mar 12, 2025

Study contacts

Ove Andersen, Professor
Contact
ove.andersen@regionh.dk
+4529333262
Mette Bendtz Lindstroem, MPH
Contact
mlin0062@regionh.dk
+4538623308
Ove Andersen, Professor
principal investigator · Department of Clinical Research, Copenhagen University Hospital, Hvidovre
Jon Ambaek Durhuus, PhD
study chair · Department of Clinical Research, Copenhagen University Hospital, Hvidovre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion